Osteal Therapeutics is a privately held, late clinical-stage developer of novel drug/device combination therapeutics to treat orthopedic infections and their consequences. The company is leveraging the ability of highly concentrated, locally delivered antimicrobials to treat the bacterial biofilms typically responsible for musculoskeletal infections while minimizing off-target tissue exposure and associated adverse effects. Osteal employs a low-risk development strategy by using approved drugs with long histories of safety and efficacy as candidates for new routes of local administration. The company’s lead candidate, VT-X7 KIT, will be indicated to treat periprosthetic joint infections and is expected to be commercially available in 2025.